Categories: News

Park Medi World Steps Up National Expansion, Targets 5,000+ Beds by FY28

All-cash acquisitions across priority markets reinforce balance sheet strength and execution discipline

- Advertisement -

NEW DELHI, Jan. 14, 2026 /PRNewswire/ — With a clear ambition to emerge as North India’s largest and most integrated hospital chain, Park Medi World Limited is accelerating a national growth strategy designed to build scale with discipline, deepen clinical capabilities, and deliver consistent, high-quality healthcare across high-potential markets. For shareholders and long-term investors, this phase marks the deliberate creation of a scalable healthcare platform built on predictable demand, strong regional fundamentals, and the ability to compound value over time.

- Advertisement -

As part of this strategy, the Company has strengthened its footprint across Delhi NCR, Uttar Pradesh, and Punjab through the acquisition of KP Institute of Medical Sciences in Agra, Febris Multispecialty Hospital in New Delhi, and Krishna Super-speciality Hospital in Punjab. These additions expand the Group’s network by approximately 810 beds through all-cash transactions, reflecting disciplined capital deployment and balance sheet strength, while advancing the roadmap to scale beyond 5,000 beds by FY28.

- Advertisement -

Commenting on the Group’s growth trajectory, Dr. Ankit Gupta, Managing Director, Park Medi World Limited, said: “Park Medi World is at a defining point in its growth journey. Our objective is not expansion for scale alone, but the creation of a high-quality, integrated hospital platform that can grow sustainably and generate long-term value. Every capital allocation decision is guided by clinical strength, integration readiness, and the ability to enhance the platform’s long-term earnings and resilience. The cluster-led model allows us to scale with control, unlock operating leverage, and improve asset productivity as we expand. As we move toward a 5,000-plus bed network by FY28, our focus remains on building institutions that are operationally strong, financially robust, and deeply trusted by patients and clinicians. We believe this approach positions Park Medi World to deliver consistent returns and durable value for all stakeholders.”

- Advertisement -

Importantly, these acquisitions are not standalone transactions, but part of a clearly sequenced growth framework. Each asset has been evaluated for market relevance, clinical depth, and integration readiness, ensuring that growth remains accretive and execution risks are managed proactively. Park Medi World’s integrated platform strategy enables faster integration, standardization of clinical and operating protocols, improved utilization of medical talent and infrastructure, and tighter cost control. This model supports margin expansion and operating leverage as scale increases, key drivers of sustainable profitability in organized healthcare.

- Advertisement -

Regionally, the Group’s expansion strengthens its position across high-growth healthcare markets. In Western Uttar Pradesh, the addition of a large multi-super-specialty facility enhances access to advanced tertiary care in an underpenetrated market. In Delhi NCR, expansion across dense urban and peri-urban catchments improves revenue density and scale in a competitive corridor. In Punjab, the move to full ownership of a stabilized hospital enables sharper execution and stronger earnings contribution.

- Advertisement -

Together, these developments reinforce Park Medi World’s intent to scale decisively yet responsibly, building a healthcare platform that combines growth, resilience, and long-term value creation as it advances toward leadership in North India’s organized healthcare sector.

- Advertisement -

About Park Group

- Advertisement -

Park Group is North India’s 2nd largest Hospital Chain, currently operating 14 hospitals with a combined capacity of 3,250 beds. Park Group is in the process of integrating an additional seven hospitals, which are under various stages of execution, and it will add 2,010 beds. These expansions will take Park Group’s total bed capacity to 5,260 beds by March 2028, underscoring its aggressive growth and leadership in healthcare delivery. The Group has established a strong presence across key cities including Delhi, Gurgaon, Faridabad, Panipat, Karnal, Sonipat, Ambala, Mohali, Patiala, Bathinda, Behror and Jaipur. Built on a commitment to accessible, high-quality healthcare, Park Group offers a comprehensive range of clinical services—spanning super-specialities such as cardiology, neurology, oncology, orthopaedics, gastroenterology, critical care, nephrology, and women & child health. Each facility is equipped with modern medical infrastructure, advanced diagnostics, 24×7 emergency support, and multi-disciplinary teams delivering evidence-based care. Through continuous expansion and strategic investments, Park Group is strengthening its mission to build a dependable, technology-enabled healthcare ecosystem that serves both metropolitan and regional communities across North India.

- Advertisement -

Logo: https://mma.prnewswire.com/media/2861485/Park_Hospitals_Logo.jpg

- Advertisement -

 

- Advertisement -

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/park-medi-world-steps-up-national-expansion-targets-5-000-beds-by-fy28–302661019.html

- Advertisement -

Recent Posts

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

8 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

8 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

8 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

8 hours ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…

8 hours ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…

8 hours ago